161 related articles for article (PubMed ID: 29435317)
1. Impact of liver volume on polycystic liver disease-related symptoms and quality of life.
Neijenhuis MK; Kievit W; Verheesen SM; D'Agnolo HM; Gevers TJ; Drenth JP
United European Gastroenterol J; 2018 Feb; 6(1):81-88. PubMed ID: 29435317
[TBL] [Abstract][Full Text] [Related]
2. The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression.
Neijenhuis MK; Kievit W; Perrone RD; Sloan JA; Erwin P; Murad MH; Gevers TJG; Hogan MC; Drenth JPH
BMC Nephrol; 2017 May; 18(1):169. PubMed ID: 28545401
[TBL] [Abstract][Full Text] [Related]
3. Modelling polycystic liver disease progression using age-adjusted liver volumes and targeted mutational analysis.
Sierks D; Schönauer R; Friedrich A; Hantmann E; de Fallois J; Linder N; Fischer J; Herber A; Bergmann C; Berg T; Halbritter J
JHEP Rep; 2022 Nov; 4(11):100579. PubMed ID: 36246085
[TBL] [Abstract][Full Text] [Related]
4. Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume.
Wijnands TF; Neijenhuis MK; Kievit W; Nevens F; Hogan MC; Torres VE; Gevers TJ; Drenth JP
Liver Int; 2014 Nov; 34(10):1578-83. PubMed ID: 24313956
[TBL] [Abstract][Full Text] [Related]
5. Severity in polycystic liver disease is associated with aetiology and female gender: Results of the International PLD Registry.
van Aerts RMM; Kievit W; de Jong ME; Ahn C; Bañales JM; Reiterová J; Nevens F; Drenth JPH
Liver Int; 2019 Mar; 39(3):575-582. PubMed ID: 30225933
[TBL] [Abstract][Full Text] [Related]
6. Development and Validation of a Disease-Specific Questionnaire to Assess Patient-Reported Symptoms in Polycystic Liver Disease.
Neijenhuis MK; Gevers TJ; Hogan MC; Kamath PS; Wijnands TF; van den Ouweland RC; Edwards ME; Sloan JA; Kievit W; Drenth JP
Hepatology; 2016 Jul; 64(1):151-60. PubMed ID: 26970415
[TBL] [Abstract][Full Text] [Related]
7. Effect of renal transcatheter arterial embolization on quality of life in patients with autosomal dominant polycystic kidney disease.
Suwabe T; Ubara Y; Sekine A; Ueno T; Yamanouchi M; Hayami N; Hoshino J; Kawada M; Hiramatsu R; Hasegawa E; Sawa N; Takaichi K
Nephrol Dial Transplant; 2017 Jul; 32(7):1176-1183. PubMed ID: 28873973
[TBL] [Abstract][Full Text] [Related]
8. Clinical Correlates of Mass Effect in Autosomal Dominant Polycystic Kidney Disease.
Kim H; Park HC; Ryu H; Kim K; Kim HS; Oh KH; Yu SJ; Chung JW; Cho JY; Kim SH; Cheong HI; Lee K; Park JH; Pei Y; Hwang YH; Ahn C
PLoS One; 2015; 10(12):e0144526. PubMed ID: 26641645
[TBL] [Abstract][Full Text] [Related]
9. Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial.
D'Agnolo HM; Kievit W; Takkenberg RB; Riaño I; Bujanda L; Neijenhuis MK; Brunenberg EJ; Beuers U; Banales JM; Drenth JP
J Hepatol; 2016 Sep; 65(3):601-7. PubMed ID: 27212247
[TBL] [Abstract][Full Text] [Related]
10. Bacterial Cholangitis in Autosomal Dominant Polycystic Kidney and Liver Disease.
Martin WP; Vaughan LE; Yoshida K; Takahashi N; Edwards ME; Metzger A; Senum SR; Masyuk TV; LaRusso NF; Griffin MD; El-Zoghby Z; Harris PC; Kremers WK; Nagorney DM; Kamath PS; Torres VE; Hogan MC
Mayo Clin Proc Innov Qual Outcomes; 2019 Jun; 3(2):149-159. PubMed ID: 31193902
[TBL] [Abstract][Full Text] [Related]
11. Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management.
Cnossen WR; Drenth JP
Orphanet J Rare Dis; 2014 May; 9():69. PubMed ID: 24886261
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology of autosomal-dominant polycystic liver disease in Olmsted county.
Suwabe T; Chamberlain AM; Killian JM; King BF; Gregory AV; Madsen CD; Wang X; Kline TL; Chebib FT; Hogan MC; Kamath PS; Harris PC; Torres VE
JHEP Rep; 2020 Dec; 2(6):100166. PubMed ID: 33145487
[TBL] [Abstract][Full Text] [Related]
13. Quality of life of patients with ADPKD-Toranomon PKD QOL study: cross-sectional study.
Suwabe T; Ubara Y; Mise K; Kawada M; Hamanoue S; Sumida K; Hayami N; Hoshino J; Hiramatsu R; Yamanouchi M; Hasegawa E; Sawa N; Takaichi K
BMC Nephrol; 2013 Aug; 14():179. PubMed ID: 23978051
[TBL] [Abstract][Full Text] [Related]
14. Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use.
Mizuno H; Sekine A; Suwabe T; Ikuma D; Yamanouchi M; Hasegawa E; Sawa N; Ubara Y; Hoshino J
PLoS One; 2022; 17(2):e0264065. PubMed ID: 35176098
[TBL] [Abstract][Full Text] [Related]
15. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.
Chrispijn M; Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Drenth JP
J Hepatol; 2013 Jul; 59(1):153-9. PubMed ID: 23499726
[TBL] [Abstract][Full Text] [Related]
16. Liver involvement in early autosomal-dominant polycystic kidney disease.
Hogan MC; Abebe K; Torres VE; Chapman AB; Bae KT; Tao C; Sun H; Perrone RD; Steinman TI; Braun W; Winklhofer FT; Miskulin DC; Rahbari-Oskoui F; Brosnahan G; Masoumi A; Karpov IO; Spillane S; Flessner M; Moore CG; Schrier RW
Clin Gastroenterol Hepatol; 2015 Jan; 13(1):155-64.e6. PubMed ID: 25111236
[TBL] [Abstract][Full Text] [Related]
17. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.
Hogan MC; Masyuk TV; Page LJ; Kubly VJ; Bergstralh EJ; Li X; Kim B; King BF; Glockner J; Holmes DR; Rossetti S; Harris PC; LaRusso NF; Torres VE
J Am Soc Nephrol; 2010 Jun; 21(6):1052-61. PubMed ID: 20431041
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.
Miskulin DC; Abebe KZ; Chapman AB; Perrone RD; Steinman TI; Torres VE; Bae KT; Braun W; Winklhofer FT; Hogan MC; Rahbari-Oskoui F; Moore CG; Flessner MF; Schrier RW;
Am J Kidney Dis; 2014 Feb; 63(2):214-26. PubMed ID: 24183837
[TBL] [Abstract][Full Text] [Related]
19. Serum bile acids associate with liver volume in polycystic liver disease and decrease upon treatment with lanreotide.
Dekker SEI; Bierau J; Giera M; Blomberg N; Drenth JPH; Mayboroda OA; de Fijter JW; Soonawala D;
Eur J Clin Invest; 2024 Apr; 54(4):e14147. PubMed ID: 38071418
[TBL] [Abstract][Full Text] [Related]
20. Questionnaire PLD-complaint-specific assessment identifies need for therapy in polycystic liver disease: A multi-centric prospective study.
Billiet A; Temmerman F; Coudyzer W; Van den Ende N; Colle I; Francque S; De Maeght S; Janssens F; Orlent H; Sprengers D; Delwaide J; Decock S; De Vloo C; Moreno C; van Malenstein H; van der Merwe S; Verbeek J; Nevens F
United European Gastroenterol J; 2023 Sep; 11(7):633-641. PubMed ID: 37278135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
